QIAGEN (QGEN) Form 144 Discloses Insider Sales Totaling 50,000 Shares

Rhea-AI Filing Summary

Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.

Positive

• Complete transaction details are provided including broker, sale dates, and aggregate market values which improves transparency.
• Acquisition history is disclosed (dates and number of performance shares), supporting Rule 144 requirements.

Negative

• Insider selling is disclosed: 18,577 shares proposed and 50,000 shares sold recently, which could be perceived negatively by some investors.
• Some filer metadata is blank or not provided (CIK/complete contact fields appear missing), reducing administrative completeness.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosure; size is immaterial relative to outstanding shares.

The filing shows a proposed sale of 18,577 shares valued at $910,286 against 216.556 million shares outstanding, representing roughly 0.0086% of the outstanding shares, which is immaterial to market capitalization. Recent reported sales of 50,000 shares on 08/13/2025 produced $2.46 million in proceeds; that volume equals about 0.023% of outstanding stock. These disclosures are required and increase transparency but do not indicate material change to capitalization or control.

Compliance/Risk Analyst

TL;DR: Filing appears compliant with Rule 144 requirements and includes standard attestation.

The form provides acquisition details (dates and nature: performance shares) and lists broker and sale dates, satisfying Rule 144 disclosure elements. The signer affirms no material nonpublic information is known; there is no indication in the filing of any trading-plan adoption or exception. From a compliance standpoint the document contains the necessary information for public notice of intended insider sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	18577	910286.00	216556000	08/14/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/27/2025	Performance Shares	Issuer			4736	02/27/2025	Not Applicable
Common	02/28/2025	Performance Shares	Issuer			4085	02/28/2025	Not Applicable
Common	02/21/2023	Performance Shares	Issuer			9756	02/21/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ROLAND SACKERS Hulsterweg 82 Venlo P7 5912 PL	Common	08/13/2025	34622	1700933.85
ROLAND SACKERS Hulsterweg 82 Venlo P7 5912 PL	Common	08/13/2025	15378	755501.15

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the QGEN Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 18,577 common shares valued at $910,286 to be sold on 08/14/2025 on the NYSE.

How many shares did the insider sell in the past three months according to this filing?

The filing reports two sales on 08/13/2025 totaling 50,000 shares for combined gross proceeds of $2,456,435.00.

What were the acquisition sources and dates for the securities to be sold?

The securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares), and 02/28/2025 (4,085 shares).

Who is the broker handling the proposed sale?

The broker listed is Morgan Stanley Smith Barney LLC, 1 New York Plaza 8th Floor New York NY 10004.

How large is the proposed sale relative to outstanding shares?

The proposed 18,577-share sale is about 0.0086% of the reported 216,556,000 shares outstanding (calculated from figures in the filing).